What is PROK's market cap?

$234.05M, based on the Nov 4 close of $1.12.

Does ProKidney pay a dividend?

No regular cash dividend has been paid in the last year.

How much of PROK is sold short?

24.6M shares, 27.4% of float, as of Oct 15, 2026.

What sector is PROK in?

Healthcare, in the Biotechnology industry.

NASDAQ · PROKHealthcareBiotechnology

ProKidney Corp. Class A Ordinary Shares (PROK)

$1.12+4.67%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1.12▼ 60.00% in range

Nov 4, 2025Low $1.07 · High $2.89Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

ProKidney closed at $1.12 on Nov 4, up 4.67%, 61.2% below its 52-week closing high. Volume of 1.2M shares was 0.83× its 20-day average (close to normal).

Split-adjusted performance: -30.0% over one month, -42.9% over six months, -60.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $150K, down 32.1% from a year earlier, with a net margin of -18948.0%.

Short interest was 24.6M shares at the Oct 15 settlement, up 3.3% from the prior report (27.4% of float, 20.8 days to cover).

Market cap$234.1M209.0M shares

Revenue · quarter$150.0K−32.1% YoY

Diluted EPS$-0.15—

P/E · TTM—P/S 286.1×

Net margin-18,948.0%Gross 100.0%

Dividend yieldNone

52-week range1.07 – 2.89−61.2% from high

Volume1.2M0.83× 20-day avg

Volatility · 60d85.6%Annualised

Short % of float27.4%20.8 days to cover

Net cash$181.6MCash $181.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −26.3%1M −30.0%3M −31.7%6M −42.9%YTD −50.0%1Y −60.7%3Y −33.7%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum34

Revenue growth29

Net margin7

Value (low P/E)—

Size48

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short24.6M+3.3% vs prior

Days to cover20.8Settled Oct 15

% of float27.4%

Short vol. 10d68.0%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
PROKProKidney	$1.12	+4.67%	−42.9%	−32.1%	−18948.0%	—	$234.1M
CABACabaletta Bio	$1.42	0.00%	−61.9%	—	—	—	$240.8M	Compare
DTILPrecision BioSciences	$8.12	+16.50%	+8.0%	−100.0%	—	—	$224.1M	Compare
FATEFate Therapeutics	$2.09	+2.45%	−8.7%	+9.2%	−1448.6%	—	$250.4M	Compare
IKTInhibikase Therapeutics	$1.57	+5.74%	−22.1%	—	—	—	$218.4M	Compare
PALIPalisade Bio	$1.25	+1.63%	−37.5%	—	−2114.8%	—	$217.8M	Compare
PLXProtalix BioTherapeutics	$2.69	+3.07%	+33.2%	+27.1%	19.0%	11.4	$216.7M	Compare
ALECAlector	$2.28	+11.22%	−11.3%	−57.8%	−692.5%	—	$254.6M	Compare
LCTXLineage Cell Therapeutics	$1.03	+1.98%	−28.0%	−61.3%	138.6%	—	$260.5M	Compare

News about ProKidney

All news →

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026GlobeNewswire Inc. · Oct 2, 2026▲ Positive ProKidney Reports Full Year 2025 Financial Results and Business HighlightsGlobeNewswire Inc. · Mar 18, 2026▲ Positive

Quick answers

What does ProKidney do?: ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells.
What is PROK's market cap?: $234.05M, based on the Nov 4 close of $1.12.
Does ProKidney pay a dividend?: No regular cash dividend has been paid in the last year.
How much of PROK is sold short?: 24.6M shares, 27.4% of float, as of Oct 15, 2026.
What sector is PROK in?: Healthcare, in the Biotechnology industry.

About ProKidney

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

HQ: Winston-Salem, NC231 employeesListed Jul 12, 2022prokidney.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology